Hepatect Cp

Hepatect Cp is a human hepatitis B immunoglobulin formulated as a sterile solution for injection. It contains purified anti‑HBs antibodies and is supplied in a ready‑to‑use vial for intravenous administration. The product is prescribed in the European Union for passive immunization against hepatitis B virus. Hepatect Cp is a prescription‑only (Rx) immunoglobulin indicated for post‑exposure prophylaxis and for preventing hepatitis B recurrence in patients after liver transplantation.

Hepatect Cp is used to provide passive immunity against hepatitis B virus in specific clinical situations.

- Post‑exposure prophylaxis for individuals who have been exposed to hepatitis B through needlestick injuries, sexual contact, or perinatal transmission. - Prevention of hepatitis B infection in newborns of hepatitis B‑positive mothers when active vaccination is delayed or contraindicated. - Prophylaxis in patients undergoing hemodialysis who are at high risk for hepatitis B exposure. - Prevention of hepatitis B recurrence after orthotopic liver transplantation in recipients receiving a hepatitis B‑positive graft. - Supplementation of hepatitis B vaccine in immunocompromised patients with inadequate serologic response.

The safety profile of Hepatect Cp reflects the typical reactions observed with human immunoglobulin products administered intravenously.

Common: - Mild fever or chills during or shortly after infusion. - Headache or fatigue. - Localized pain, erythema, or swelling at the injection site. - Nausea or mild gastrointestinal discomfort.

Serious: - Acute allergic reactions such as urticaria, angioedema, or anaphylaxis. - Severe hypotension or cardiovascular collapse. - Hemolysis or renal impairment related to immune complex formation. - Transfusion‑related acute lung injury (TRALI).

Before prescribing Hepatect Cp, clinicians should evaluate several precautionary factors to minimize risk and ensure appropriate use.

- Assess patient history for hypersensitivity to human immunoglobulins or blood‑derived products. - Verify hepatitis B surface antigen status and anti‑HBs antibody levels to determine need for passive immunization. - Monitor vital signs and observe for infusion‑related reactions during the first administration. - Adjust infusion rate in patients with cardiovascular disease or compromised circulatory status. - Use caution in pregnant or breastfeeding women, as safety data are limited. - Ensure proper aseptic technique to prevent contamination of the injectable solution.

Hepatect Cp may interact with other agents that affect immune function or infusion safety.

Avoid: - Concurrent administration of other blood‑derived products (e.g., plasma, albumin) without appropriate spacing, which can increase the risk of immune complex formation. - Live vaccines administered within 4 weeks of Hepatect Cp, as passive antibodies may interfere with vaccine efficacy.

Use with caution: - Immunosuppressive drugs (e.g., corticosteroids, calcineurin inhibitors) that may alter the patient’s response to passive antibodies. - Anticoagulants or antiplatelet agents, because infusion reactions can occasionally trigger bleeding or thrombocytopenia. - Renal‑impairing medications, as immune complexes may affect kidney function in susceptible individuals.